About Us
Shenox introduction
Shenox aims to use good science to develop drug products that improve the quality of care and the quality of life to patients. Shenox focuses on the development of transdermal and transmucosal delivery of psychiatric medicines, including Major Depressive Disorder (MDD), neuropathic pain, and attention deficit hyperactivity disorder (ADHD).
The product, SHX-001, is targeted to reduce the adverse events and the addiction of ketamine for the treatment of depression, by means of innovative pharmacology design and precise transdermal delivery control. The Shenox team discovered that a gradual and prolonged ascending pharmacokinetics profile design of SHX-001 can bring an entirely new pharmacology of using ketamine to treat depression.
In parallel, Shenox has develop PigPerm, which is a comprehensive permeation and prediction platform, that can facilitate the translation of preclinical data to clinical study outcomes. Shenox also has an experienced team to streamline the 505(b)(2) regulatory path of approval, and the global commercialization of drug products.
Our Team
CEO, Chairman
Tang Huadong, Ph.D.
CEO, Chairman,
Dr. Tang serves as CEO of Shenox, which he co-founded in 2015. He also serves as chairman of GDB, which he founded in 2017. Dr. Tang is an expert in PK/PD and earned his PhD in Pharmaceutical sciences from the University of Arizona. He holds a bachelor degree in Microbiology from Fudan University.
He was responsible for human pharmacokinetic/dose prediction and early clinical pharmacology in most project pharmacological assessments. A predictive clinical pharmacokinetic model (Tang's Coefficients; FCIM) was created that is widely used by the pharmaceutical academic and industrial communities. These models are important tools for evaluating the drug-made nature of new drugs and clinical pharmacological research.
He specializes in FDA communication, specializing in quantitative pharmacology (conversion, clinical), designing optimized and efficient 505b(2) paths.
Chief Operating Officer
Steven Dinh, Sc.D.
Chief Operating Officer
Dr. Dinh serves as COO in Shenox and GBD since 2020.
Dr. Dinh earned his Sc.D in Chemical Engineering from MIT. He is a Fellow of the American Society of Pharmaceutical Scientists, and a Fellow of the American Institute for Medical and Biological Engineering.
Prior to his current position, Dr. Dinh was EVP/CSO of CutisPharma, VP/CSO of Noven, VP of Research and Technology of Emisphere, and other company executives.
Dr. Dinh Led the development and successful commercialization of a number of products on the market, including multiple NDA approved products. He also led the advancement of oral (macromolecule) and dermal delivery technologies to support the development of innovative products from ideation to commercialization.
Chief Strategy Officer
Michael Mayersohn, Ph.D.
Chief Strategy Officer
Dr. Mayersohn serves as Chief Strategy Officer in Shenox, which he co-founded in 2015. He also serves as the Chief Strategy Officer in GDB since 2017.
Dr. Mayersohn earned his Ph.D. from SUNY Buffalo Pharmacy. He is a Fellow of the American Society of Pharmaceutical Scientists, the Academy of Pharmacology, and the American Society of Clinical Pharmacology. He also served on the FDA Pharmacy Advisory Board; and Chairman of the Pharmacology Committee of the American Pharmacopeia.
Dr. Mayersohn is a professor in University of Arizona for over 40 years. He is an authoritative expert in the field of PK. He also served as an expert witness in pharma litigations. He is also experienced in IP matters.
Scientific Advisor
Hock Tan, Ph.D.
Scientific Advisor
Dr Tan was also a Co-Founder in Shenox.
Dr. Tan earned his Ph.D. in Chemical Engineering from Queen’s University at Kingston.
He was the founder of Bionex Pharmaceuticals LLC. Prior to his current position, he used to work in Kos Pharmaceuticals, Lavipharm Laboratories Inc, and Ethicon. He is an expert in the field of transdermal patch and oral thin film.
Scientific Advisory Board
Maurizio Fava, M.D.
Dr. Maurizio Fava is Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), director, Division of Clinical Research of the MGH Research Institute, executive director of the Clinical Trials Network and Institute, (MGH), associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School. Dr. Fava is a world leader in the field of depression and has published more than 800 original articles in medical journals with an h index of over 140.
Tom Laughren, M.D.
Dr. Laughren was formerly Director of the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA. Dr. Laughren was responsible for overseeing the review of all psychiatric drug development activities conducted under INDs (Investigational New Drug) and the review of all NDAs (New Drug Applications) and supplements for new psychiatric drug claims. Prior to joining the FDA in September 1983, Dr. Laughren was affiliated with the VA Medical Center in Providence, RI, and was on the faculty of the Brown University Program in Medicine.
Philip D. Walson, M.D.
Dr. Walson is Board Certified in Pediatrics, Clinical Pharmacology and Medical Toxicology with >35 years of experience in pediatric/adult clinical trials. He is past president/ founder of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, author of more than 200 publications, and a past Chair of the American Academy of Pediatrics' Committee on Drugs and Section on Clinical Pharmacology and Therapeutics. He was a professor at the University of Arizona, Children's Hospital at Columbus, Cincinnati Children's Hospital and is currently a visiting Professor at the Georg-August-Universitat Medical School, Goettingen, Germany.
